RETHINK-ALZ
Simufilam 100 mg for Mild to Moderate Alzheimer’s Disease
A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects Inclusion Criteria Age 55-90 years Have a reliable study partner, an identified adult who has sufficient contact to knowledgeably report on the subject’s daily cognition, function, behavior, safety, compliance and adherence. Have a clinical diagnosis of mild-to-moderate AD Visual and
The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) Read More »
Dr. Gengo shares information from a recent article. The use of Motrin and Tylenol when getting a vaccine possibly may have a negative impact on the immune response to the vaccine. The recommendations: Use those medications only if needed. Using the medications before the vaccine to prevent side effects seems to have the most noticeable impact.
Vaccines and Pain/Fever Medicines Read More »
By: Bennett Myers, MD, Director of DENT Multiple Sclerosis & Immunology Center and the DENT Spasticity Clinic. The following information is from the Mayo Clinic in Rochester, Minnesota. It is considered by many to be the top health care center in the world. The 2 vaccines available have already been given to over 10 million Americans. Outside of
Covid-19 Vaccine Myths & Facts Read More »